Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

What this Trial Is About

Researchers are studying new biological markers to better understand the development and progression of Mycobacterium abscessus lung disease in patients with cystic fibrosis. The goal is to enhance knowledge of how this lung disease evolves by examining immune responses and inflammation related to the infection. This observational study involves several groups, including cystic fibrosis patients with chronic M. abscessus infection, those with M. abscessus pulmonary disease, patients without any history of M. abscessus infection, and healthy controls. Participants will undergo evaluations using advanced techniques such as Luminex and single-cell RNA sequencing (scRNAseq) to assess specific cell populations and circulating immune factors linked to the lung disease. The study aims to correlate early changes in immune cell profiles and markers with disease progression and clinical outcomes. These evaluations take place during normal clinical visits, following standard procedures at the participating centers. During the study, participants will have their immune cell populations and protein markers measured to track disease development and progression. The main outcome is to profile these cellular and molecular markers one month after enrollment. The study involves informed consent and includes patients aged 18 years and older. Researchers will monitor inflammatory responses and interactions between cellular and humoral immunity to support a deeper understanding of disease mechanisms.

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis